Item 7.01 Regulation FD Disclosure ; AAR CORP.’s Vice President and Chief Financial Officer, Michael J. Sharp, presented at the KeyBanc Capital Markets Industrial, Automotive & Transportation Conference in Boston. ; Attached as Exhibit 99.1 are the slides used by Mr. Sharp in his presentation.
Item 7.01 Regulation FD Disclosure · AAR CORP.’s Vice President, Chief Financial Officer and Treasurer, Michael J. Sharp, presented at the Cowen and Company 37th Annual Aerospace/Defense & Transportation Conference on Thursday, February 4, 2016 in New York City. Attached as Exhibit 99.1 are the slides used by Mr. Sharp in his presentation. The information in this Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of t...
Booz Allen Hamilton Holding Corporation ; Lloyd W. Howell, Jr. ; Executive Vice President, Chief Financial Officer and Treasurer
SECURITIES AND EXCHANGE COMMISSION · Washington, D.C. 20549 · FORM 8-K · CURRENT REPORT · PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 · Date of Report (Date of Earliest Event Reported) – January 11, 2006 · WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter)
Additional Information and Where to Find It · In connection with the proposed transaction between GE and Baker Hughes, the new NYSE listed corporation (“Newco”) will prepare and file with the SEC a registration statement on Form S-4 that will include a combined proxy statement/prospectus of Newco and Baker Hughes (the “Combined Proxy Statement/Prospectus”). Baker Hughes and Newco will prepare and file the Combined Proxy Statement/Prospectus with the SEC, and Baker Hughes will mail the ...
Forward-Looking Statements · Certain statements in this communication may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s expectations; beliefs; plans; strategies; business or financial prospects or outlook; future shareholder value; expected growth and value creation; earnings expectations; expected drivers and guidance; profitability; investments, including free cash flow an...
Item 7.01 Regulation FD Disclosure. On January 3, 2019, BioXcel Therapeutics, Inc. (the “Company”) held an investor conference call and discussed the results of the study described in Item 8.01 below and the Company’s BXCL501 program. In connection with the investor call, the Company prepared presentation materials (“the Presentation Materials”), a copy of which are furnished as Exhibit 99.1 to this current report on Form 8-K. The call will be available via a live, listen-only webcast ...
UNITED STATES · SECURITIES AND EXCHANGE COMMISSION · SCHEDULE 14A · Proxy Statement Pursuant to Section 14(a) · of the Securities Exchange Act of 1934 · (Amendment No. ) · Filed by the Registrant ☒ · Filed by a Party other than the Registrant ☐ · Check the appropriate box:
UNITED STATES SECURITIES AND EXCHANGE COMMISSION ; Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ; o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ; o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
nc10021295x2_defa14a.htm DEFA14A ; UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ; SCHEDULE 14A (Rule 14a-101) ; Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )